Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Leukemia Therapeutics Market 2026 by its Scientific Reviews and Key Side-Effects

Author: Satish Sraje
by Satish Sraje
Posted: May 17, 2019
leukemia therapeutic

Leukemia also known as blood cancer hinders ability of an individual to fight infection. It is characterized by formation of tumors in blood-forming tissues including bone marrow. Various type of leukemia include acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia. Fatigue, weight loss, frequent infections and easy bleeding or bruising are some of the symptoms of this disease. Treatment of early leukemia include monitoring and severe leukemia is treated with chemotherapy, followed by radiation and stem-cell transplant. According to Center for Disease Control and Prevention (CDC), in the U.S. around 45,360 people were diagnosed with leukemia in 2013, leading to 23,549 fatalities (13,625 men and 9,924 women). The condition is more prevalent among men than women.

Download The PDF Brochure:

Leukemia Therapeutics Market

On the basis of disease condition, the global leukemia therapeutics market is segmented into:

  • Acute lymphocytic leukemia

  • Chronic lymphocytic leukemia

  • Acute myeloid leukemia

  • Chronic myeloid leukemia

On the basis of treatment, the global leukemia therapeutics market is segmented into:

  • Immunotherapy

  • Targeted Therapy

  • Bone Marrow Transplant

  • Stem Cell Therapy

High diagnosis rate in developed economies supporting the leukemia therapeutics market growth in those regions

According to the Centre for Disease Control (CDC), around 14.1 million people were diagnosed with cancer in 2012, resulting in around 8.2 million fatalities. Around 19.3 million new cases of cancer are projected to be diagnosed by 2025. Leukemia cases are projected to be more in the developed economies such as North America and Europe, owing to genetic mutations caused by radiation exposure. There are about 54,270 new cases of leukemia in the U. S. annually. Leukemia makes up about 3% of all new cancer cases. According to the World Cancer Research Fund, one third of the cancer cases occur in economically developed economies such as US and Europe, owing to lack of physical activity, obesity, and/or poor nutrition. Furthermore, around 90% of the leukemia occur in the middle age and develop with the aging.

Furthermore, in emerging economies of Asia Pacific such as China and India, the leukemia therapeutics market is expected to grow at significant rate due high unmet medical needs. However, low diagnosis rate of leukemia and lack of proper healthcare facilities in few Asian and African countries is restraining growth of the leukemia therapeutics market in these regions.

Key players operating in the global leukemia therapeutics market include GSK, Eisai C., Pfizer, Biogen, Celgene, Novartis AG, Genzyme Corporation, Roche, and Bristol Myers Squibb Company (BMS). Major market players are focused on new product launch, product pipeline, merger & acquisitions, clinical trials and collaboration & agreements to maintain leading position in market. For instance, Novartis recently launched tyrosine kinase receptor FLT-3 for the treatment of leukemia. Pfizer implemented product expansion strategy to capture major market share, received Food and Drug Approval (FDA) for Bosulif drug.

Click To Read More Leukemia Therapeutics Market

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

About the Author

Contact Us: Mr.Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702

Rate this Article
Leave a Comment
Author Thumbnail
Please or Join to add a comment.
Author: Satish Sraje

Satish Sraje

United States

Member since: Nov 01, 2018
Published articles: 144

Related Articles